ARIAD Announces Updated Clinical Results on AP26113 in Patients with Non-Small Cell Lung Cancer

ARIAD Pharmaceuticals, Inc.

today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The study confirms compelling clinical evidence of the anti-tumor activity of AP26113 at multiple dose levels in patients with anaplastic lymphoma kinase positive (ALK+) NSCLC, including brain metastases, and initial clinical evidence of anti-tumor activity in patients with epidermal growth factor receptor mutant (EGFRm) NSCLC. The study identified a recommended Phase 2 dose of 180 mg administered orally once daily. The Phase 2 portion of the trial is now open and enrolling patients at